One of the big challenges involved in engineering CAR-T cells to attack cancer revolves around its extension from B cell malignancies--where it's been remarkably successful--to solid tumors. A new mouse study from Ziopharm, one of the players in this field, suggests that leveraging a drug's affinity for EGFR, or other overexpressed proteins, may offer a route around toxicity issues that make solid tumors a hard target.
Investigators at the Salk Institute have blazed a new trail branching out from the closely studied mGluR5 pathway in the brain, and they say it could ultimately lead to new therapies to treat neurodevelopmental disorders like autism and schizophrenia. Read more >>
A global team of scientists working with Johns Hopkins' Jordan Green has developed a new nonviral gene therapy for brain cancer, successfully testing it in the lab in cell lines as well as rat models for the disease. Read more >>
POPULAR COMMENT THREADS
By studying a group of outliers in a Colombian family known for the prevalence of early-onset Alzheimer's, investigators at UC Santa Barbara believe they may have fingered a new drug target that could delay the disease by a decade or more.
A year ago, researchers at Johns Hopkins concluded that chemical alterations in the SKA2 gene appeared to be linked with a higher risk for suicide. And now another team has followed up, exploring biomarkers from the change-up in the SKA2 gene that could also be used to identify who might be most at risk for post-traumatic stress disorder, or PTSD.
Researchers in the neurology department at Johns Hopkins have shown that a generic selective serotonin reuptake inhibitor may help human stroke victims.
Alzheimer's disease is often characterized by the appearance of protein aggregates that are toxic in the brain. For over 30 years it has been known that protein fragments called beta-amyloid peptides generate these insoluble deposits. Now researchers have characterized a new protein aggregate at play that needs to be carefully considered by Alzheimer's drug investigators.
Researchers at the Translational Genomics Research Institute (TGen) say they have identified a potential gene associated with the initiation of nonalcoholic fatty liver disease, the most common cause of liver damage.
Investigators at Memorial Sloan Kettering Cancer Center have changed the rules of the clinical trial game in the first of what they say will be a new wave of studies that examine a drug's potential based on a broad patient population who share the same genetic mutation rather than cancer type.
From Our Sister Sites
C.R. Bard is facing pushback over one of its blood-clot devices, as reports surface that the company's product caused serious injuries--and in some cases, death--in patients, and that Bard allegedly tried to sweep the problems under the rug.
The MD Anderson Cancer Center in Houston is becoming the preferred partner of choice among a growing group of immuno-oncology players looking to develop a new generation of drugs. This afternoon it was Cellectis' turn to join the migration south, sayings its researchers in New York will be working with some of the top experts at MD Anderson as the biotech advances a group of off-the-shelf CAR-T cell therapies.